Diabetes drugs need long-term CV safety data, US panel says
This article was originally published in Scrip
Executive Summary
All drugs in development for type 2 diabetes should undergo long-term safety trials to rule out an excessive cardiovascular risk, the US FDA's outside advisors recommended on July 2nd.